Vicore Pharma Holding AB
STO:VICO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.9665
23.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vicore Pharma Holding AB
Revenue
Vicore Pharma Holding AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Vicore Pharma Holding AB
STO:VICO
|
Revenue
kr104.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
265%
|
CAGR 10-Years
N/A
|
||
Biogaia AB
STO:BIOG B
|
Revenue
kr1.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
||
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr814.5m
|
CAGR 3-Years
58%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
||
Vitrolife AB
STO:VITR
|
Revenue
kr3.6B
|
CAGR 3-Years
32%
|
CAGR 5-Years
21%
|
CAGR 10-Years
22%
|
||
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr25.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
||
BioArctic AB
STO:BIOA B
|
Revenue
kr616m
|
CAGR 3-Years
115%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
Vicore Pharma Holding AB
Glance View
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.
See Also
What is Vicore Pharma Holding AB's Revenue?
Revenue
104.2m
SEK
Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Revenue amounts to 104.2m SEK.
What is Vicore Pharma Holding AB's Revenue growth rate?
Revenue CAGR 5Y
265%